Donor source and outcomes
| Reference . | N . | TRM . | OS . |
|---|---|---|---|
| Kröger et al. 200913 | 103 PMF, post-ET MF, post-PV MF HLA matched: 82 HLA mismatched: 21 | At 1 y MRD: 10% MUD: 13% MMUD: 38% | At 5 y MRD/MUD: 74% MMUD: 38% P = .03 |
| Rondelli et al. 201440 | 66 PMF, post-ET MF, post-PV MF MRD: 30 Haplo: 2 MUD: 25 MMUD: 9 | MRD: 22% MUD: 59% | MRD: 75% MUD: 32% |
| Gupta et al. 201441 | 233 PMF MRD: 79 MUD: 104 MMUD: 50 | At 1 y: 18% At 5 y: 24% MUD: 3.92 MMUD: 9.37 (P < .0001) | Adjusted OS at 5 y MRD: 56% MUD: 48% MMUD: 34% (P = .002) |
| Raj et al. 201915 | PMF 42, secondary MF 14 56 MMRD | 35% (95% CI, 22%-48%) @ 1 y | 61% (95% CI, 48%-74%) @ 1 y |
| McLornan et al. 202142 | 4142 patients PMF 3239, post-ET MF 494, post-PV MF 409 MRD: 1430 MUD: 1554 MMRD: 226 MMUD: 537 CB: 31 | NRM hazard ratio: MRD: 0 MUD: 1.3 (1.11-1.54), P = .001 MMRD: 1.76 (1.32-2.36) P ≤ .001 MMUD: 1.9 (1.56-2.31), P ≤ .001 | OS hazard ratio MRD: 0 MUD: 1.21 (1.06-1.38), P = .005 MMRD: 1.51 (1.16-1.97), P = .002 MMUD: 1.67 (1.41-1.97), P ≤ .001 |
| Kunte et al. 202214 | 69 patients PMF 35, post-ET MF 19, post-PV MF 15 | @ 1 y: 21% (95% CI, 12%-32%) @ 3 y: 23% (95% CI, 14%-34%) | @ 1 y: 74% (95% CI, 61%-83%) @ 3 y: 72% (95% CI, 59%-81%) |
| Reference . | N . | TRM . | OS . |
|---|---|---|---|
| Kröger et al. 200913 | 103 PMF, post-ET MF, post-PV MF HLA matched: 82 HLA mismatched: 21 | At 1 y MRD: 10% MUD: 13% MMUD: 38% | At 5 y MRD/MUD: 74% MMUD: 38% P = .03 |
| Rondelli et al. 201440 | 66 PMF, post-ET MF, post-PV MF MRD: 30 Haplo: 2 MUD: 25 MMUD: 9 | MRD: 22% MUD: 59% | MRD: 75% MUD: 32% |
| Gupta et al. 201441 | 233 PMF MRD: 79 MUD: 104 MMUD: 50 | At 1 y: 18% At 5 y: 24% MUD: 3.92 MMUD: 9.37 (P < .0001) | Adjusted OS at 5 y MRD: 56% MUD: 48% MMUD: 34% (P = .002) |
| Raj et al. 201915 | PMF 42, secondary MF 14 56 MMRD | 35% (95% CI, 22%-48%) @ 1 y | 61% (95% CI, 48%-74%) @ 1 y |
| McLornan et al. 202142 | 4142 patients PMF 3239, post-ET MF 494, post-PV MF 409 MRD: 1430 MUD: 1554 MMRD: 226 MMUD: 537 CB: 31 | NRM hazard ratio: MRD: 0 MUD: 1.3 (1.11-1.54), P = .001 MMRD: 1.76 (1.32-2.36) P ≤ .001 MMUD: 1.9 (1.56-2.31), P ≤ .001 | OS hazard ratio MRD: 0 MUD: 1.21 (1.06-1.38), P = .005 MMRD: 1.51 (1.16-1.97), P = .002 MMUD: 1.67 (1.41-1.97), P ≤ .001 |
| Kunte et al. 202214 | 69 patients PMF 35, post-ET MF 19, post-PV MF 15 | @ 1 y: 21% (95% CI, 12%-32%) @ 3 y: 23% (95% CI, 14%-34%) | @ 1 y: 74% (95% CI, 61%-83%) @ 3 y: 72% (95% CI, 59%-81%) |
CB, cord blood; ET, essential thrombocythemia; HLA, human leukocyte antigen; MMRD, mismatched related donor; NRM, non-relapse mortality; PV, polycythemia vera; TRM, treatment-related mortality.